Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START-or-NOT trial: Irbesartan after AKI in ICU survivors
2020-000414-16Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of irbesartan in acute kidney failure (AKF), chronic kidney disease (CKD) and cardiac morbidity (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Cardiovascular and global outcome at 1 year. Started Aug 2024; status: active.
02
Drugs
irbesartan
03
Conditions
acute kidney failure (AKF)chronic kidney disease (CKD)cardiac morbidity
Beyond the preview
Go deeper on 2020-000414-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000414-16.